Published in final edited form as:

Retina. 2018 September ; 38(9): 1725–1730. doi:10.1097/IAE.0000000000001957.

Scleral Pits in Choroideremia: Implications for Retinal Gene Therapy

Abdullah A. Al-Qahtani, MD^{1,4}, Shakoor Ba-Ali, MD^{2,3}, Talal Alabduljalil, MD, FRCSC¹, Aaron S. Coyner, BS¹, Rachel C. Patel, MD¹, Richard G. Weleber, MD¹, Aniz Girach, MD⁵, Søren Kirchhoff Christensen, MD^{2,3}, Michael Larsen, DMSc^{2,3}, Mark E. Pennesi, MD, PhD¹, and Paul Yang, MD, PhD¹

¹Casey Eye Institute, Oregon Health & Science University, Portland, OR, U.S

²Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark

³Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

⁴Department of Ophthalmology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

⁵NightstaRx Ltd, London, United Kingdom

Abstract

Purpose—We report a novel finding on spectral domain optical coherence tomography (OCT) in patients with choroideremia, which we describe as scleral pits (SCP).

Methods—Cross sectional observational case series of 36 patients with choroideremia, who underwent ophthalmic examination and multimodal imaging, including OCT of the macula. Optical coherence tomography images were reviewed for SCP, which were defined as discrete tracts of hyporefectivity that traverse the sclera with or without the involvement of Bruch membrane, retinal pigment epithelium, and retina. Unpaired two-tailed t-test with Welch's correction was used for statistical analysis.

Results—Of the 36 patients, 19 had SCP in at least one eye. SCP were confined to areas of advanced chorioretinal degeneration and never involved the foveola. Type 1 SP affected only sclera, while type 2 SCP also involved Bruch's membrane and the RPE. Type 3 SCP additionally had a full thickness retinal defect. Patients with SCP were significantly older (51 ± 2 vs. 33 ± 4 years; $p < 0.05$) and had lower best-corrected visual acuity ($20/160$ vs. $20/30$ or 0.9 ± 0.2 vs. 0.2 ± 0.07 logMAR; $p < 0.05$) than patients without SCP. Patients with SCP had a greater myopic refractive error compared to patients without SCP (-2.6 ± 0.5 vs. -0.3 ± 0.5 D; $p < 0.05$), but there was no significant correlation between the number of SCPs with refraction. Short posterior ciliary arteries were observed to enter the eye through one type 3 SCP.

Correspondence: Paul Yang, MD, PhD, 3375 SW Terwilliger Blvd, Portland, OR 97239, Tel: 503-494-8386, Fax: 503-418-2218, yangp@ohsu.edu.

Note: Abdullah A. Al-Qahtani and Shakoor Ba-Ali contributed equally as primary authors.

Competing Interest Statement: This study was an investigator-initiated study conducted using data from patients who were part of a multi-center choroideremia natural history study sponsored by NightstaRx, Ltd (London, UK). Dr. Aniz Girach is an employee of NightstaRx, otherwise none of the other authors declare any competing interests or received any payment from NightstaRx for the development of this study or for manuscript preparation.

Conclusion—Scleral pits are, to the best of our knowledge, a novel optical coherence tomography finding in advanced choroideremia that likely represents the abnormal juxtaposition of short posterior ciliary arteries with the retina.

Keywords

Choroideremia; Scleral pits; CHM; short posterior ciliary arteries

Introduction

Choroideremia is an X-linked (Xq21) recessive disease caused by mutations in the *CHM* gene, which encodes the Rab escort protein-1 (REP1).^{1–4} It is a relatively rare disease with a prevalence of 1:50,000.⁵ Early clinical manifestations include a loss of peripheral and night vision, which progress to tunnel vision and eventual loss of central vision in late stages of the disease.⁶ During childhood, the fundus characteristics may manifest as peripapillary atrophy and widespread pigment clumping at the level of the retinal pigment epithelium, which then evolve later into lobular atrophic areas involving retina, RPE, and the choriocapillaris.⁷ These areas can coalesce resulting in a pale fundus from the revelation of underlying scleral tissue covered by preserved large choroidal vessels.^{8–10} Although the disease primarily manifests in males, carrier females may also be affected, but usually they demonstrate patchy and less severe degeneration due to random lyonization of the X-chromosome.^{11,12} The order of cell death in choroideremia is unclear. Most reports show that RPE is primarily affected with secondary degeneration of the photoreceptors and choriocapillaris, however other studies alternatively suggest that photoreceptors degenerate first or that both RPE and photoreceptors degenerate independently with secondary damage to choroid.^{13–17}

Multimodal imaging utilizing OCT and other imaging techniques in choroideremia are limited due to rarity of the disease. Previous reports have demonstrated changes such as choroidal neovascularization, cystoid macular edema, epiretinal membranes, outer retinal tubulations, intralaminar bridges, macular hole formation, and macular holes complicated by retinal detachment.^{15,18–23} The OCT study by Jacobson et al. showed that retinal remodeling in choroideremia starts with retinal thickening, followed by photoreceptor degeneration, RPE depigmentation, and then retinal thinning with neuronal cell death and loss of laminar architecture.¹⁴ A recent study utilizing *en face* OCT and OCT angiography showed that at different stages RPE and choriocapillaris loss exceeded photoreceptor loss.²⁴ In this study, we report a novel OCT finding in choroideremia that is correlated with disease course and may play a role in pre-surgical considerations for gene and cell-based therapies.

Methods

The study was performed in accordance with the tenets of the Declarations of Helsinki and the study protocol was approved by each institution's research ethical committee. Informed consent was obtained from all subjects. Clinically confirmed cases of choroideremia were reviewed from our pool of patients seen at Casey Eye Institute (Portland, OR, USA) and Department of Ophthalmology, Rigshospitalet-Glostrup (Copenhagen, Denmark). Inclusion

criteria were male subjects aged 18 years old, having a clinical phenotype with or without genetic diagnosis of choroideremia; and having disease clinically visible within the macular region. The exclusion criteria were history of amblyopia in either eye, concurrent retinal disease of other etiology, or presence of motion or media-opacity artifact in the OCT image.

All patients had detailed clinical examination including best corrected visual acuity (BCVA), intraocular pressure (IOP) and refraction. Snellen chart or Early Treatment of Diabetic Retinopathy Study (ETDRS) chart was used for visual acuity testing which were converted to logMAR visual acuities for statistical purposes. Manifest refraction was documented for all eyes except in case of pseudophakia or poor visual acuity. After dilation, patients underwent imaging with spectral domain OCT, infrared reflectance (IR), fluorescein angiography (FA), and indocyanine green angiography (ICG) using the Spectralis (Wavelength: 870 nm; Heidelberg Engineering Co, Heidelberg, Germany), 30 or 50 degree color fundus photography using the FF450 (Carl Zeiss Meditec, Dublin, CA), and wide-field fundus autofluorescence (FAF) using the Optos 200Tx confocal scanning laser ophthalmoscope (Optos PLC, Marlborough, MA). The OCT was obtained with high resolution mode with 97 b-scans centered on fovea. Since our cohort consisted of patients with a wide range of age and two different clinical centers, it was not possible to perform an identical scanning protocol on all patients.

Scleral pits (SCP) were defined as discrete tracts of low reflectivity that traversed the sclera with or without involvement of Bruch's membrane, retinal pigment epithelium (RPE), and retina. The number of SCP were counted for each eye within the area of the OCT volume scan, which consists of $20^{\circ} \times 20^{\circ}$ area or $20^{\circ} \times 15^{\circ}$ area centered on the fovea. To fully visualize the extent of certain SCP, enhanced-depth imaging optical coherence tomography (EDI-OCT) was additionally performed in 5 subjects. The SCP identified on OCT were further characterized on IR and FAF. All data collected from the right and left eye from each patients were highly correlated (data not shown), and thus the averaged values of both eyes were used to represent each patient. Unpaired two-tailed t-tests with Welch's correction was used for statistical analysis.

Results

Of 36 patients with choroideremia included in the study, 19 had SCP in at least one eye (53%). Of those, 13 had SCP in both eyes. Genetic testing demonstrating a mutation in *CHM* were available for 26 patients (16 with SCP vs. 10 without SCP; Table 1). Regardless of genetic confirmation, all patients had clinical findings and a family history consistent with choroideremia. Two eyes were excluded: one due to presence of a choroidal neovascular membrane and the other due to a technical error. Scleral pits were localized to areas of advanced chorioretinal degeneration, but never involved the foveola. Three types of SCP were observed (Figure 1). Type 1 had intact Bruch's membrane, residual RPE, and retina. Type 2 had a break in Bruch's membrane and RPE with or without focal retinal excavation, whereas type 3 had focal full thickness retinal loss. Type 1 SCP were difficult to detect on fundus examination or with IR or FAF imaging, and were only visible on OCT. Type 2 and 3 SCP were seen on fundus examination as focal round depressions that were hyporeflexive on IR and hypoautofluorescence on FAF, which was indicative of the RPE defect. EDI-OCT

performed in 5 subjects showed that SCP extended deeply into the outer sclera. Fundus angiography was performed for one patient (#P10) with type 3 SCP wherein the cavitation appeared to cause an interruption in a retinal vessel. FA revealed that the retinal vessel filled normally but had a circuitous route following a path around the edge of the SCP lesion (Figure 2), while ICG showed no discrete cyanescence that correlated with the SCP.

Patients with SCP were significantly older (51 ± 2 vs. 33 ± 4 yrs; $p < 0.05$) and had poorer acuity ($20/160$ vs. $20/30$ or 0.9 ± 0.2 vs. 0.2 ± 0.06 logMAR; $p < 0.05$) compared to patients without SCP (Figure 3). Patients with SCP had a greater myopic refractive error compared to patients without SCP (-2.6 ± 0.5 vs. -0.3 ± 0.5 D; $p < 0.05$). However, there was no significant correlation between the number of SCPs with age, BCVA, or refraction. There was no significant difference in IOP between the group with SCP and the group without SCP. This study was not powered to determine correlations based on types of SCP due to the low numbers of subjects and presence of more than one type in some eyes.

Discussion

We have characterized SCP as a novel OCT finding in patients with choroideremia, which are discrete fovea-sparing lesions that involve the macula, and appear as dramatic structural defects of the sclera, and to varying degrees, Bruch's membrane, the RPE, and retina. The spectrum of SCP in choroideremia appear phenotypically different from those typically found in pathologic myopia that are characterized as a posterior thinning and out-pouching of the scleral on OCT.^{25,26} However, some SCP in choroideremia resemble the peripapillary lesions in pathologic myopia as described by Ohno-Matsui and colleagues.²⁷ In addition, Ohno-Matsui et al also showed that short posterior ciliary arteries (SPCA) penetrate the eye at the sites of SCP, which is similar to our findings in choroideremia. While the choroideremia patients in our cohort were not high myopes, the patients with SCP were significantly more myopic than those without SCP, suggesting that moderate levels of myopia may exacerbate choroidal thinning and contribute to risk of developing SCP in choroideremia. Patients with SCP were also significantly older and had significantly poorer visual acuity than those without SCP, which suggests that SCP are a phenomenon that develops late in the disease course of choroideremia. Previous reports showed that choroideremia becomes more asymmetric in older patients²⁸, which may explain the unilaterality of SCP in about a third of our patients.

Previous histological reports of choroideremia have demonstrated degeneration in the retina, RPE, and choriocapillaris^{12,13}, however there are no known histological descriptions that correspond with SCP as described in this study. Without histopathology, it is unknown if SCP are still lined with vascular endothelial cells, and if type 3 SCP are indeed full thickness perforations of the globe or if a thin hyporeflexive membrane between the two spaces remains. Based on the results of angiography and similarities to peripapillary SCP in high myopia, the etiology of SCP in choroideremia is most likely due to the abnormal juxtaposition of penetrating short posterior ciliary arteries with the retina as a result of severe choroidal atrophy.

It is unknown whether SCP are specific to choroideremia, or may also be found in other choroidal dystrophies. In addition, this study was also limited by the retrospective nature and relatively small sample size; however choroideremia is a rare disease. Studies in larger groups of patients with choroideremia will be necessary to determine if the different types of SCP identified in this study are correlated with different *CHM* mutations.

Scleral pits are, to our knowledge, a novel OCT finding in choroideremia especially in patients with reduced visual acuity and advanced disease. It is unknown whether vitrectomy or subretinal injection may disrupt the residual Bruch's membrane and RPE layer of an SCP, which would hasten drainage and reduce anatomical sequestration of subretinal-delivered therapeutic agents, especially as it pertains to retinal gene and cell-based therapies. If so, treatment efficacy may be affected, not only by limiting retention of the therapeutic agent, but also by compromising subretinal space-associated immune tolerance from potential exposure of the vector capsid or stem-cell antigens to choroidal dendritic cells and lymphatics. These potential issues may be especially problematic for type 3 SCP, even if a thin membrane remains that cannot not be visualized by OCT separating the two compartments. Additional studies will be needed to determine if areas with numerous SCP should be avoided in ongoing retinal gene therapy clinical trials for choroideremia.

Acknowledgments

Funding:

National Institute of Health: 1K08 EY0231186-01(MEP); 1K08EY026650-01(PY); P30 EY010572 (Casey Eye Institute)

Research to Prevent Blindness: unrestricted departmental funding to Casey Eye Institute

Choroideremia Research Foundation

Danish Association of the Blind (SKC)

Foundation Fighting Blindness: C-CL-0711-0534-OHSU01 (Casey Eye Institute); CD-NMT-0714-0648 (PY); CD-NMT-0914-0659 (MEP).

References

1. Cremers FP, Armstrong SA, Seabra MC, Brown MS, Goldstein JL. REP-2, a Rab escort protein encoded by the choroideremia-like gene. *The Journal of biological chemistry*. 1994; 269:2111–7. [PubMed: 8294464]
2. van den Hurk JA, Schwartz M, van Bokhoven H, et al. Molecular basis of choroideremia (CHM): mutations involving the Rab escort protein-1 (REP-1) gene. *Human mutation*. 1997; 9:110–7. [PubMed: 9067750]
3. Cremers FP, van de Pol DJ, van Kerkhoff LP, Wieringa B, Ropers HH. Cloning of a gene that is rearranged in patients with choroideraemia. *Nature*. 1990; 347:674–7. [PubMed: 2215697]
4. Seabra MC, Mules EH, Hume AN. Rab GTPases, intracellular traffic and disease. *Trends Mol Med*. 2002; 8:23–30. [PubMed: 11796263]
5. MacDonald IM, Sereda C, McTaggart K, Mah D. Choroideremia gene testing. *Expert Rev Mol Diagn*. 2004; 4:478–84. [PubMed: 15225095]
6. Heon E, Alabduljalil T, McGuigan ID, et al. Visual Function and Central Retinal Structure in Choroideremia. *Investigative ophthalmology & visual science*. 2016; 57:OCT377–87. [PubMed: 27409497]

7. Khan KN, Islam F, Moore AT, Michaelides M. Clinical and Genetic Features of Choroideremia in Childhood. *Ophthalmology*. 2016; 123:2158–65. [PubMed: 27506488]
8. Zinkernagel MS, MacLaren RE. Recent advances and future prospects in choroideremia. *Clinical ophthalmology*. 2015; 9:2195–200. [PubMed: 26648685]
9. Karna J. Choroideremia. A clinical and genetic study of 84 Finnish patients and 126 female carriers. *Acta Ophthalmol Suppl*. 1986; 176:1–68. [PubMed: 3014804]
10. Coussa RG, Kim J, Traboulsi EI. Choroideremia: effect of age on visual acuity in patients and female carriers. *Ophthalmic genetics*. 2012; 33:66–73. [PubMed: 22060191]
11. Lyon MF. Gene action in the X-chromosome of the mouse (*Mus musculus* L.) *Nature*. 1961; 190:372–3. [PubMed: 13764598]
12. Flannery JG, Bird AC, Farber DB, Weleber RG, Bok D. A histopathologic study of a choroideremia carrier. *Investigative ophthalmology & visual science*. 1990; 31:229–36. [PubMed: 2303326]
13. MacDonald IM, Russell L, Chan CC. Choroideremia: new findings from ocular pathology and review of recent literature. *Survey of ophthalmology*. 2009; 54:401–7. [PubMed: 19422966]
14. Sun LW, Johnson RD, Williams V, et al. Multimodal Imaging of Photoreceptor Structure in Choroideremia. *PloS one*. 2016; 11:e0167526. [PubMed: 27936069]
15. Jacobson SG, Cideciyan AV, Sumaroka A, et al. Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations. *Investigative ophthalmology & visual science*. 2006; 47:4113–20. [PubMed: 16936131]
16. Syed N, Smith JE, John SK, Seabra MC, Aguirre GD, Milam AH. Evaluation of retinal photoreceptors and pigment epithelium in a female carrier of choroideremia. *Ophthalmology*. 2001; 108:711–20. [PubMed: 11297488]
17. Tolmachova T, Anders R, Abrink M, et al. Independent degeneration of photoreceptors and retinal pigment epithelium in conditional knockout mouse models of choroideremia. *J Clin Invest*. 2006; 116:386–94. [PubMed: 16410831]
18. Goldberg NR, Greenberg JP, Laud K, Tsang S, Freund KB. Outer retinal tubulation in degenerative retinal disorders. *Retina*. 2013; 33:1871–6. [PubMed: 23676993]
19. Zinkernagel MS, Groppe M, MacLaren RE. Macular hole surgery in patients with end-stage choroideremia. *Ophthalmology*. 2013; 120:1592–6. [PubMed: 23562166]
20. Shinoda H, Koto T, Fujiki K, Murakami A, Tsubota K, Ozawa Y. Clinical findings in a choroideremia patient who underwent vitrectomy for retinal detachment associated with macular hole. *Jpn J Ophthalmol*. 2011; 55:169–71. [PubMed: 21400066]
21. Palejwala NV, Lauer AK, Weleber RG. Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab. *Clinical ophthalmology*. 2014; 8:1675–9. [PubMed: 25214760]
22. Syed R, Sundquist SM, Ratnam K, et al. High-resolution images of retinal structure in patients with choroideremia. *Investigative ophthalmology & visual science*. 2013; 54:950–61. [PubMed: 23299470]
23. Khachatryan V, Sirunyan AM, Tumasyan A, et al. Search for heavy resonances decaying to two Higgs bosons in final states containing four b quarks. *Eur Phys J C Part Fields*. 2016; 76:371. [PubMed: 28280444]
24. Anandi P, Jain NA, Tian X, et al. Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors. *Bone Marrow Transplant*. 2016; 51:1101–6. [PubMed: 27042843]
25. Ohno-Matsui K, Akiba M, Moriyama M. Macular pits and scleral dehiscence in highly myopic eyes with macular chorioretinal atrophy. *Retin Cases Brief Rep*. 2013; 7:334–7. [PubMed: 25383824]
26. Pedinielli A, Souied EH, Perrenoud F, Leveziel N, Caillaux V, Querques G. In vivo visualization of perforating vessels and focal scleral ectasia in pathological myopia. *Investigative ophthalmology & visual science*. 2013; 54:7637–43. [PubMed: 24194186]
27. Ohno-Matsui K, Akiba M, Moriyama M, et al. Acquired optic nerve and peripapillary pits in pathologic myopia. *Ophthalmology*. 2012; 119:1685–92. [PubMed: 22494632]

28. Aleman TS, Han G, Serrano LW, et al. Natural History of the Central Structural Abnormalities in Choroideremia: A Prospective Cross-Sectional Study. *Ophthalmology*. 2017; 124:359–73. [PubMed: 27986385]

Summary Statement

Scleral pits are a novel OCT finding associated with advanced choroideremia that likely represent the abnormal juxtaposition of residual short posterior ciliary arteries with the retina.

Figure 1.

Three types of Scleral pits (SCP). Upper row, A–D: Type 1 SCP, patient #P3 right eye. A) OCT reveals subtle focal posterior bowing of the retina, retinal pigment epithelium (RPE), and choroid above an area of scleral cavitation and oblique tract. This type 1 SCP is visible as a hyporeflective spot on infrared (B, arrow) and a subtle grey lesion on color fundus photography (C, arrow), but is not visible on fundus autofluorescence (FAF; D, arrow). Middle row, E–H: Type 2 SCP, patient #P3, left eye. E) OCT shows prominent posterior bowing of the retina with no discernible retinal laminations, RPE, or choroidal layers, culminating in a sclera cavitation and tract at a right angle to the retinal surface. Type 2 SCP are easily visible as a prominent hyporeflective spot on infrared (F, arrow), a dark spot on color (G, arrow), and hypoautofluorescent spot on FAF (H, arrow). Lower row, I–L: Type 3, patient #P10, right eye. I) OCT reveals a full-thickness focal defect of the retina, RPE, and choroid with no visible membrane separating the equally hyporeflective space of the vitreous and scleral tract. Type 3 SCP are similar in appearance to Type 2 SCP on infrared, color, and FAF (J–L, arrows).

Figure 2.

Angiogram of a Type 3 scleral pit. Magnified color photograph of a type 3 scleral pit (A, blue arrowhead) from figure 1–K (patient #P10, right eye) showing apparent interruption of a segment of a large retinal vein. Fluorescein angiogram reveals that the retinal vein is patent with decreased flow in semi-circinate path (B, blue arrowhead). Short posterior ciliary arteries appear to enter the globe through this pit (A, black arrowheads; B, white arrowheads).

Figure 3. Patients with scleral pits were significantly older (A), and had worse best-corrected visual acuity (B) than patients without scleral pits. SCP, scleral pits; BCVA, best-corrected vision; asterick, $p < 0.05$.

Table 1

Patients with Choroideremia and SCP

Patients	Age (years)	<i>CHM</i> mutation
P1	36	Arg253Stop
P2	51	Hemizygous A>G nucleotide substitution at position of intron 6
P3	59	c.1044_1047delCAGC
P4	66	c.1584?1587delTGTT
P5	54	ND
P6	48	ND
P7	35	p. Tyr323Stop:c.969T>A
P8	65	c.1010_1015del TCATGCinsCA
P9	52	c.525_526delAG
P10	49	ND
P11	47	c.1609+1delG
P12	56	c.907C>T
P13	61	c.1179insC
P14	67	c.1153insC
P15	44	del exon 1–15
P16	56	c.555–556 del AG
P17	49	c. 2T>A
P18	26	del exon 13
P19	56	c.1680–1681del TT

ND: no mutation detected in *CHM* or genetic testing not available